Compare Expensify Inc (EXFY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Expensify Inc trades at $2.44 (market cap $223.41M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 22.5× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EXFY | TVTX | |
|---|---|---|
Market Cap | $223.41M | $5.02B |
Volume | 450,483 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $2.72 | $67.52 |
52-Week Low | $0.75 | $26.79 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $163.03M | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.45, showing modest daily gains of 0.41%. The stock exhibits a bullish technical signal with strong moving average support. Fundamentally, the company maintains solid revenue around $142M but faces profitability challenges with negative net margins. Recent quarterly earnings show mixed results with two beats and one miss. Analyst sentiment leans positive with a 50% buy rating and $13.75 consensus price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with substantial analyst upside but persistent profitability concerns. The company's expansion into European markets and AI integrations provide growth catalysts, though negative earnings and cash flow volatility remain key risks. Investors should weigh the significant price target premium against the company's ongoing transition to profitability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
